Hepatic stem cells and cancers: a pathologist's view.

IF 1.3 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2015-10-01 DOI:10.2217/hep.15.25

Neil D Theise

引用次数: 2

Abstract

Neil Theise speaks to Georgia Patey, Commissioning Editor: Neil Theise is a diagnostic liver pathologist, adult stem cell researcher and complexity theorist in New York City, where he is a Professor of Pathology at the Mount Sinai Beth Israel Medical Center of Icahn School of Medicine at Mount Sinai. He received his medical degree from Columbia University College of Physicians and Surgeons, where he also received his training in Anatomic Pathology. Subspecialty training was pursued in gastrointestinal (NYU), liver (Royal Free Hospital) and liver transplant (Mount Sinai, NYC) pathology. His earliest research focus was on defining the premalignant dysplastic nodules in human chronic liver disease. He revised understandings of human liver microanatomy, which in turn, led directly to identification of possible liver stem cell niches and the marrow-to-liver regeneration pathway. He is considered a pioneer of multiorgan adult stem cell plasticity. His publications on these topics in model systems and human liver stem cells have been highlighted on a record five covers of Hepatology.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肝干细胞与癌症：病理学家的观点。

Neil Theise采访了委托编辑Georgia Patey：Neil Thease是纽约市的诊断性肝脏病理学家、成人干细胞研究员和复杂性理论家，也是西奈山伊坎医学院西奈山贝斯以色列医学中心的病理学教授。他在哥伦比亚大学内科医生和外科医生学院获得了医学学位，并在那里接受了解剖病理学的培训。在胃肠道（纽约大学）、肝脏（皇家免费医院）和肝移植（纽约西奈山）病理学方面进行了亚专业培训。他最早的研究重点是确定人类慢性肝病中的癌前增生异常结节。他修改了对人类肝脏显微解剖的理解，这反过来又直接导致了对可能的肝干细胞小生境和骨髓到肝脏再生途径的识别。他被认为是多器官成人干细胞可塑性的先驱。他在模型系统和人类肝干细胞方面发表的关于这些主题的文章在《肝病学》创纪录的五本封面上得到了强调。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.